Results 1 to 10 of about 42,043 (296)

Anticancer Activity of Pyrimethamine via Ubiquitin Mediated Degradation of AIMP2-DX2

open access: yesMolecules, 2020
While aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is a tumor suppressor, its exon 2-depleted splice variant (AIMP2-DX2 or shortly DX2) is highly expressed in human lung cancer, and the ratio of DX2 to AIMP2 increases according
Dae Gyu Kim   +5 more
doaj   +2 more sources

Dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a systematic review and individual participant data meta-analysisResearch in context [PDF]

open access: yesEClinicalMedicine
Summary: Background: High-grade Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in east and southern Africa has prompted trials evaluating intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine as an ...
Michelle E. Roh   +25 more
doaj   +2 more sources

Risk of Congenital Toxoplasmosis in Newborns from Mothers with Documented Infection: Experience from Two Referral Centres [PDF]

open access: yesPathogens
During pregnancy, primary Toxoplasma gondii infection can cause congenital toxoplasmosis (CT). We described the newborns’ outcomes from a multicentre cohort of mothers with seroconversion (SC) at different gestational ages.
Alice Bonetti   +11 more
doaj   +2 more sources

Study of anti-Toxoplasma gondii effect of mPEG–PCL copolymeric loaded with pyrimethamine, in vitro [PDF]

open access: yesAMB Express
The discovery of new drugs with minimal toxicity is crucially important in the search for effective treatments for toxoplasmosis. The study aimed to assess the effectiveness of pyrimethamine-loaded mPEG–PCL copolymeric nanoparticles (mPEG–PCL–Pyr ...
Mobina Gholami   +5 more
doaj   +2 more sources

In Vitro Inhibitory Activity of Corilagin and Punicalagin Against Toxoplasma gondii and Their Mechanism(s) of Action [PDF]

open access: yesAntibiotics
Background/Objectives: Toxoplasmosis is a zoonotic disease caused by Toxoplasma gondii. The parasite infection in humans continues to rise due to an increasing seroprevalence rate in domestic and wild warm-blooded animals that serve as a major reservoir ...
Nicole T. Green-Ross   +5 more
doaj   +2 more sources

Pyrimethamine poisoning. [PDF]

open access: bronzeBMJ, 1973
O Akinyanju   +2 more
openalex   +4 more sources

Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase

open access: yesPharmaceuticals, 2021
Trypanosoma and Leishmania parasites are the etiological agents of various threatening neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, and various types of leishmaniasis.
Giusy Tassone   +8 more
doaj   +1 more source

Dihydrofolate Reductase Inhibitors: The Pharmacophore as a Guide for Co-Crystal Screening

open access: yesMolecules, 2021
In this work, co-crystal screening was carried out for two important dihydrofolate reductase (DHFR) inhibitors, trimethoprim (TMP) and pyrimethamine (PMA), and for 2,4-diaminopyrimidine (DAP), which is the pharmacophore of these active pharmaceutical ...
João A. Baptista   +7 more
doaj   +1 more source

Paediatric malaria case-management with Artemether-Lumefantrine in Zambia: a repeat cross-sectional study [PDF]

open access: yes, 2007
BACKGROUND Zambia was the first African country to change national antimalarial treatment policy to artemisinin-based combination therapy – artemether-lumefantrine.
Dejan Zurovac   +36 more
core   +16 more sources

Pioneer Use of Antimalarial Transdermal Combination Therapy in Rodent Malaria Model

open access: yesPathogens, 2023
We have previously reported 1,2,6,7-tetraoxaspiro [7.11]nonadecane (N-89) as a promising antimalarial compound. In this study, we evaluated the effect of transdermal therapy (tdt) of N-89 in combination (tdct) with other antimalarials as an application ...
Nagwa S. M. Aly   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy